Publications en collaboration avec des chercheurs de Hospital Universitario La Fe (51)

2024

  1. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial

    Haematologica, Vol. 109, Núm. 2, pp. 543-552

  2. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  3. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  4. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

    Leukemia, Vol. 38, Núm. 9, pp. 1929-1937

  5. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

    Frontiers in immunology, Vol. 14, pp. 1310211

  2. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

    HemaSphere

  3. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818

  4. Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8

    Cancers, Vol. 15, Núm. 15

  5. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

    Cell Reports Medicine, Vol. 4, Núm. 12

  6. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project

    Orphanet Journal of Rare Diseases, Vol. 18, Núm. 1

  7. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

    European Journal of Haematology, Vol. 111, Núm. 3, pp. 485-490

2022

  1. ALL-268 Genetic Classification of B-Cell Precursor Adult Acute Lymphoblastic Leukemia Patients Enrolled in LAL19 Trial from the Pethema Group: Response to Treatment and Survival

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S199

  2. Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

    Value in Health, Vol. 25, Núm. 10, pp. 1760-1767

  3. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

    British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538

  4. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain

    Leukemia and Lymphoma

2021

  1. Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

    Leukemia Research, Vol. 109

  2. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

    Blood, Vol. 137, Núm. 14, pp. 1879-1894

2020

  1. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

    Cancer Medicine, Vol. 9, Núm. 7, pp. 2317-2329

  2. Helpful criteria when implementing ngs panels in childhood lymphoblastic leukemia

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-15